Long-term Follow-up of Patients with Intermediate-risk Neuroblastoma Treated with Response- and Biology-Based Therapy: A Report From the Children’s Oncology Group Study ANBL0531
Long-term Follow-up of Patients with Intermediate-risk Neuroblastoma Treated with Response- and Biology-Based Therapy: A Report From the Children’s Oncology Group Study ANBL0531
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives
- Updates in Diagnosis, Management, and Treatment of Neuroblastoma
- Coexpression of MYCN and ALK Induces Neuroblastoma-Like Tumors From Human iPS Cell-Derived Cranial Neural Crest Cells.
- Emerging clinical and research approaches in targeted therapies for high-risk neuroblastoma
- Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High‑Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study